Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Thoracic 1Plasma cell 1

Conditions

Carcinoma, Non-Small-Cell Lung 114Neoplasms 28Lung Neoplasms 24Non-Squamous Non-Small Cell Lung Cancer 21Pancreatic Neoplasms 13Colorectal Neoplasms 6Neoplasm Metastasis 5Breast Neoplasms 4Respiratory Tract Neoplasms 3Respiratory Tract Diseases 3Lymphoma 3Thoracic Neoplasms 2Solid Tumors 2Recurrence 2Neoplasms by Site 2Lung Diseases 2Familial ependymoma 2Ependymoma 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Carcinoma 2Bronchial Neoplasms 2Advanced Solid Tumors 2Vascular Diseases 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Smoking 1Small Cell Lung Carcinoma 1

Interventions

Rituximab 63Cyclophosphamide 37Brentuximab Vedotin 22Bendamustine Hydrochloride 22pembrolizumab 20fludarabine 20Gemcitabine 20Doxorubicin 20Prednisone 19ibrutinib 17Vincristine 16obinutuzumab 14Lenalidomide 13Nivolumab 10Rifampin 8parsaclisib 7duvelisib 7atezolizumab 7Vorinostat 7Dexamethasone 7Azacitidine 7spartalizumab 6loncastuximab tesirine 6MLN 8237 6venetoclax 5ixazomib 5glofitamab 5fludarabine phosphate 5durvalumab 5acalabrutinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma × Erlotinib Hydrochloride × Clear all
NCT00705874 2016-07-21

Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma

Progen Pharmaceuticals

Phase 1 Completed
172 enrolled 13 charts
Lymphoid

Lymphoma, Neoplasms

NCT01602289 2015-06-08

A Study of LY2875358 in Japanese Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
17 enrolled
LymphoidThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma

NCT00725634 2014-01-27

P05538

AVEO Pharmaceuticals, Inc.

Phase 1 Completed
41 enrolled
LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡